Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Mineralys Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$23.62

-0.34 (-1.42%)

D 36Pipeline Score Overvalued Biotech · Clinical
Market Cap
2.46 B
EPS
-2.06
P/E Ratio
-
Value Trade
203.94 M
SEC Financials
Q1 2026

  • Dilution Risk

    60%

  • R&D Expenses

    24.36 M

  • Operating CF

    -39.47 M

  • Total Assets

    652.86 M

  • Total Liabilities

    652.86 M

  • Equity

    638.14 M

  • D/E Ratio

    12,345

9.38 %
Week
2.61 %
1 Month
7.22 %
3 Month
-27.86 %
6 Month
41.47 %
5 Year
41.47 %
All Time
Cash Data
Caution

  • Cash Position

    112.78 M

  • Monthly Burn

    13.16 M

  • Runway

    7.5 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 6, 2026
Overview
Volume
1.82 M
52 Week Range
12.59 - 47.65
% held by Insiders
26.48 %
% held by Institutions
82.69 %
Enterprise Value
1.82 B
Total Shares
79.18 M
Short %
18.73 %
Float Shares
50.59 M
Company Description
HQ: 150 N. RADNOR CHESTER RD., RAD...
Employees:76
https://mineralystx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
lorundrostat adults with hypertension
PDUFA
—
Small Molecules
Cardiovascular System
lorundrostat adults with hypertension
PDUFA
—
Small Molecules
Cardiovascular System
lorundrostat adults with hypertension
PDUFA
—
Small Molecules
Cardiovascular System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D36
Pipeline Score
$567M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 44%
Small Cap
(rank 508 of 905)
Percentile Rank
Mineralys Therapeutics, Inc. faces pipeline headwinds (36/100), with $1.2B risk-adjusted pipeline value, led by lorundrostat in Hypertension (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
lorundrostat
Small molecule		HypertensionPhase 3NCT0596843048% $951M ACTIVE NOT_RECRUITING 2,444 AVERAGE C (51) Dec 1, 2026LOW_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
lorundrostat
uncontrolled hypertension,resistant hypertension,chronic kidney disease,obstructive sleep apnea
Phase 3
2025-08-13
lorundrostat
uncontrolled hypertension,resistant hypertension,chronic kidney disease,obstructive sleep apnea
Phase 3
2025-08-13
lorundrostat
uncontrolled hypertension,resistant hypertension,chronic kidney disease,obstructive sleep apnea
Phase 3
2025-08-13
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MLYS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MLYS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLYS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLYS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MLYS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MLYS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2027-01-150 0.00 0 0 - - - - - -
2027-01-150 0.00 0 0 - - - - - -
2027-01-150 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Mineralys Therapeutics, Inc. (MLYS) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How MLYS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Hypertension #3 of 16 PHASE 3 lorundrostat
LLY ALNY UTHR
$9.41B 0.98 CONTENDER